[Thymogen in the treatment of type-1 diabetes mellitus].
Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency. It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation. Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients. The scheme of thymogen administration is suggested.
Zhuk
E A
EA
Galenok
V A
VA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004151:Dipeptides; D004341:Drug Evaluation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage*; D013997:Time Factors
D000276:Adjuvants, Immunologic; D004151:Dipeptides; D010455:Peptides; C060736:thymogen